RHUMBLINE ADVISERS

Position in PRME — Prime Medicine, Inc.

CIK 1115418 BOSTON, MA

Position in PRME

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$430,822

+$33,166 QoQ

Shares Held

116,754

+2.2% QoQ

Ownership

0.064%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#65

of 186 holders

Holding Since

Jun 2023

11 quarters on record

Voting authority Sole 27% Shared 0% None 73%

Healthcare · as of Jun 30, 2026

RHUMBLINE ADVISERS holds $1,404,724,682 across 329 Biotechnology names. PRME ranks #197 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	396,380	$196,893,837
2	REGN	Regeneron Pharmaceuticals, Inc.	157,794	$98,390,870
3	MRNA	Moderna, Inc.	809,853	$56,714,005
4	ALNY	Alnylam Pharmaceuticals, Inc.	165,579	$49,844,246
5	INCY	Incyte Corp	428,533	$48,578,500
6	RVMD	Revolution Medicines, Inc.	226,008	$42,326,778
7	ROIV	Roivant Sciences Ltd.	1,178,789	$41,717,342
8	JAZZ	Jazz Pharmaceuticals plc	163,018	$39,282,447

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$430,822	116,754	+2.2%	Shares	Sole	2026-08-12
2026-03-31	$397,656	114,269	+5.4%	Shares	Sole	2026-05-12
2025-12-31	$376,179	108,409	-1.3%	Shares	Sole	2026-02-13
2025-09-30	$608,219	109,787	+12.1%	Shares	Sole	2025-11-06
2025-06-30	$241,990	97,972	+39.9%	Shares	Sole	2025-08-12
2024-09-30	$271,081	70,047	-0.1%	Shares	Sole	2024-11-12
2024-06-30	$360,349	70,107	+33.5%	Shares	Sole	2024-08-01
2024-03-31	$367,584	52,512	+3.3%	Shares	Sole	2024-05-09
2023-12-31	$450,601	50,858	-0.2%	Shares	Sole	2024-02-08
2023-09-30	$486,148	50,959	+8.3%	Shares	Sole	2023-11-09
2023-06-30	$689,472	47,063	—	Shares	Sole	2023-08-08
No filing history on record for this holder in this stock.